To conclude, the present study demonstrates that AAV1-mediated scFv-MC1 gene therapy holds promise as translational treatment for Alzheimer’s disease, and that the concurrent administration of scFvs targeting early-conformational and late-phosphorylation changes does not result in any advantage in preclinical models of anti-tau immunotherapy, compared to targeting MC1-misfolded tau alone. This evidence concerns the gene ATP7A and Alzheimer disease.